Gregory K. Stapley
Analyst · Avondale Partners
Thanks, Christopher. Hi, everyone. Since the filing of our Form 10 back in November, we've made tremendous progress to bringing the spin and creation of CareTrust to fruition. Yesterday, we filed an updated draft to our Form 10 with the SEC. It includes additional carve out -- it includes additional information about the transaction, as well as pro forma financial information based on Q3 2013 carve out financials for the property business. We expect to update the pro forma financials again with Q4 numbers in the next draft. Please remember that the pro forma financials are only an accounting method of presenting carve out historical financials and not a projection of what will happen in the future. For more useful data, including a better look at CareTrust's current post-spin projections, you will find forecasted rental revenues, G&A expenses, interest expense and other forward-looking information in the MD&A section starting on approximately Page 70 of the revised Form 10. Although the Form 10 still contains a few blanks, we believe that the revisions made to date are generally responses to the SEC's comments to our original filing, and they should significantly advance the ball. I'd refer you to the revised Form 10 for the updates and a more complete description of the proposed transaction. In addition, we're pleased to report that one of the key gating items for the spin, the issuance of an IRS private letter ruling, appears to be imminent. The PLR contains the basic rulings we need from the IRS to proceed, with the assurance, that we'll be able to execute the spin on a tax-free basis to our shareholders. We received the fax copy of the ruling from the IRS yesterday, but it's not official until we receive the actual hard copy in the mail. However, this is a very positive development. This was one of several significant hurdles we needed to clear before the spin and we're pleased to have it almost behind us. We have also tentatively finalized the post-spin capital structure for CareTrust and Ensign. The new structure leaves, as Christopher said, Ensign health enabled to execute its business model without interruption, and simultaneously gives CareTrust sufficient assets and capital availability to get off to a good start. Among other things, it includes a $260 million bond issue, revolving credit facilities for each of Ensign and CareTrust in the face amount of $150 million each and a $50 million loan commitment from one of our long-time lending partners who'll be instrumental in the capitalization of the REIT. You can find information on the REIT's initial capitalization in the Form 10's MD&A as well. Perhaps more importantly, and really excited about this, we successfully on-boarded Bill Wagner as the new CFO for the REIT. Bill has long and deep experience in REITs, in general, and healthcare REITs in particular, as his resume includes significant experience at Ernst & Young [indiscernible]; also at Sunstone Hotels, a lodging REIT; and at Nationwide Health Properties, the $7 billion healthcare REIT that was acquired by Ventas in 2011. Bill is here today. And we're excited to have him on the team, and he's already adding tremendous value daily. We have also committed 2 of the 3 independent board members we've initially named to serve on CareTrust's Board of Directors. David Lindahl is Managing Director of HPSI, a well-known GPO serving healthcare and institutional clients nationwide. And Gary Sabin is the Chairman and CEO of Excel Trust, a very successful retail and office REIT based in San Diego. Both have much to contribute, and we're excited that these experienced and outstanding business leaders have signed on to join us in this endeavor. In addition, we're pleased to report that several other highly qualified candidates who expressed interest in being a part of CareTrust, and we look forward to completing the board roster very soon. We would remind you that the capitalization, the rent and everything else we've done to structure this transaction has almost nothing to do with the actual fair value of the assets and everything to do with our plan and intent to create 2 healthy platforms for growth. In addition, it has almost nothing to do with any incidental value inherent in the spin itself, and again, everything to do with the far greater value we see on the horizon as CareTrust and Ensign both grow and thrive and return value to shareholders over the long haul. In that vein, we also remind you that CareTrust that its biggest advantage will be our healthy landlord-tenant relationship with Ensign. Ensign is one of the industry's premier operating companies and a true trophy tenant. As I've said before, both CareTrust will be completely independent and will not be Ensign's financing arm that some have assumed. We believe that our Ensign pedigree, together with Ensign's strong track record of operating performance and clinical excellence, will provide CareTrust with a solid and multifaceted foundation on which to build into the future. So with respect to the spin, there are many details yet to be addressed. We currently project that the timing of the actual spinoff will slip slightly from our previously announced end of Q1 target into the early part of Q2. But that said, we think we're starting to see the light at the end of the tunnel and we remain firmly committed to getting there. Finally, just as a personal note. It appears that this will be my last earnings call here at Ensign before the spinoff. And though I -- you can't really do it justice here in a brief earnings call, I just want to say what a pleasure and honor it's been to work with my colleagues here at Ensign. Many of you know that I handed off my General Counsel role to Bev Wittekind a few years ago, and as expected, she's done a terrific job. I also have another great successor in Chad Keetch, who's now stepping into the industry relations, acquisitions and investor relations roles I filled here. In both cases, I leave these functions in stronger hands than they've been in, and I'm confident that both Bev and Chad will serve the company, its partners and shareholders as well as -- or actually, better than I have. In addition, I also want to mention how much I've enjoyed interacting with the many analysts and investors we've been privileged to have follow us here at Ensign. These interactions have been tremendously awarding for me, and I hope that you will all continue to follow and invest in CareTrust and Ensign and that my association with each of you will continue. And with that, I'll turn the call back to Christopher.